Imfinzi gains EU approval in resectable NSCLC, bolstering AstraZeneca’s oncology pipeline
AstraZeneca’s Imfinzi-based regimen approved in the EU to cut lung cancer recurrence by 32%—learn how this could redefine early-stage NSCLC treatment. Read More
EU approves Enhertu as first HER2-targeted therapy for HR-positive, HER2-low metastatic breast cancer
Discover how Enhertu’s EU approval is transforming care for HR-positive, HER2-low and HER2-ultralow breast cancer, and what it means for AstraZeneca’s future. Read More
AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy. Read More
AstraZeneca moves deeper into cell therapy with $1bn EsoBiotec acquisition
AstraZeneca’s $1 billion acquisition of EsoBiotec signals a major shift in cell therapy innovation. Find out how this deal could transform cancer treatment. Read More
Amgen and AstraZeneca’s Tezspire achieves key milestone in Phase 3 nasal polyps trial
Amgen and AstraZeneca have revealed promising results from the Phase 3 Waypoint trial, demonstrating that Tezspire (tezepelumab-ekko) delivers significant and sustained relief for patients suffering ... Read More
AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge in total revenue, reaching $54.1 billion. This ... Read More
AstraZeneca to expand Canadian operations with $570m investment
AstraZeneca, a leading global pharmaceutical company, has announced a C$820 million (US$570 million) investment in Canada, marking a significant step in its efforts to expand ... Read More
Roche secures FDA approval for HER2-ultralow metastatic breast cancer diagnostic
Roche has received FDA approval for an expanded use of its PATHWAY HER2 (4B5) test, marking a significant breakthrough in breast cancer diagnostics. This development ... Read More
ENHERTU gains FDA approval for HER2 low or ultralow metastatic breast cancer treatment
Daiichi Sankyo and AstraZeneca’s ENHERTU (fam-trastuzumab deruxtecan-nxki) has secured approval from the U.S. Food and Drug Administration (FDA) for treating adults with unresectable or metastatic ... Read More
Datroway approved in US: A new era in metastatic breast cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan), a first-in-class TROP2-directed antibody-drug conjugate (ADC) developed by AstraZeneca ... Read More